RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
- no estimate extracted1 study · 43 participantsLow
Findings
What do systematic reviews say?
272 questions · 286 findings · 20 reviews · Schizophrenia
No studies found 49 · 17.1%GRADE not reported 30 · 10.5%Very low 88 · 30.8%Low 42 · 14.7%Moderate 73 · 25.5%High 4 · 1.4%
RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
- RR 3.05 [1.12, 8.31]1 study · 62 participantsLow
RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Adverse events: General: Severe adverse event · patients with schizophrenia
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Relapse · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes global state: Relapse (any reason) ‐ long term Number of… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
- RR 2.13 [0.84, 5.43]1 study · 63 participantsVery low
RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
1 finding from 1 review
- RR 1.24 [0.98, 1.57]2 studies · 467 participantsModerate
CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE
Mental state: No 20% response (as defined by PANSS/BPRS total change) · patients with schizophrenia
RISPERIDONE + CLOZAPINE showed no clear difference in mental state: no clinically significant response in psychotic… compared with PLACEBO + CLOZAPINE (low certainty).
1 finding from 1 review
- RR 1.15 [0.93, 1.42]2 studies · 98 participantsLow
CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
- 1.13 [0.53, 2.42]3 studies · 167 participantsVery low
CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE
Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) · patients with schizophrenia
RISPERIDONE + CLOZAPINE showed no clear difference in global state: no significant clinical improvement ‐ CGI short term compared with PLACEBO + CLOZAPINE (low certainty).
1 finding from 1 review
- RR 1.12 [0.87, 1.44]1 study · 68 participantsLow
CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)
Clinical response: no clinically significant response in mental state: 20% to 50% reduction in PANSS total score · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyRR 0.82 [0.4, 1.68]1 study · 60 participantsVery low
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)
Weight gain · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes adverse effects: weight gain compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyRR 0.4 [0.08, 1.9]1 study · 60 participantsVery low
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)
Clinical response: mean score/change in global state · people with treatment‐resistant schizophrenia
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 1 participantsGRADE not reported
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · people with treatment‐resistant schizophrenia
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsVery low
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)
Leaving the study early · people with treatment‐resistant schizophrenia
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsVery low
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)
Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010)
Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyRR 0.8 [0.28, 2.27]1 study · 24 participantsVery low
CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010)
Weight gain · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found